On todays news
Sarepta will be very interested
Why?
Because their DMD drug patent expires
But
They could license our drug in combination and that will add on more years of exclusivity…$$
Now, here’s the thing
if ATL1102 shows that it can increase dystrophin: that would be a game changer…
because Sarepta is yet to prove to the FDA efficacy.
Sarepta will have to take us out min $2 per share
We wait
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-83
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |